Trials begin for a new type of face mask
22 April 2020 RMIT fashion and textiles experts have designed a new style of protective face mask for healthcare workers. The staff and student team has sewn 100 of the prototype masks as part of a Federal Government…
Immutep completes enrollment for INSIGHT-004 study
23 April 2020 Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced that the last patient has been enrolled and safely dosed for the second cohort of the INSIGHT-004 Phase I clinical…
PolyNovo first Canadian BTM use
23 April 2020 PolyNovo is pleased to announce the first use of NovoSorb BTM in Canada. This case was initiated by one of Canada’s leading surgeons who is a key opinion leader in this field. PolyNovo has not…
NovoSorb® BTM Feasibility Study Results for US FDA
21 April 2020 PolyNovo is pleased to share the summary of results for the CP-002 Feasibility Study to assess the safety and effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the treatment of severe skin burn injuries. This…
VivaZome Therapeutics Pty Ltd and ToolGen, Inc. extend collaboration agreement based on successful proof-of-concept outcomes
22 April 2020 Melbourne, Australia and Seoul, South Korea: VivaZome Therapeutics Pty Ltd (“VivaZome”) and ToolGen, Inc (“ToolGen”) have announced the extension of a collaborative research project exploring the gene-editing of cells for enhanced exosome production. Under the…
Bosch Australia’s Manufacturing Solutions business unit awarded COVID-19 project by Grey Innovation
21 April 2020 Bosch Australia’s Manufacturing Solutions division (BAMS) has been awarded a AUD $1 million project as part of the industry consortium to build ventilators in Victoria. The notus Emergency Invasive Ventilator Program, a Grey Innovation led…
Victoria’s coronavirus (COVID-19) modelling confirms staying at home saves lives
20 April 2020 The Victorian Government has released modelling to provide greater understanding of the spread of coronavirus in Victoria. The modelling, done by Victoria’s epidemiological experts at the Department of Health and Human Services and in collaboration…
Partnership To Revolutionise Cancer Diagnosis
21 April 2020 Medical technology company Sienna Cancer Diagnostics has partnered with The University of Adelaide in an exclusive worldwide licencing agreement to develop a unique cancer probe with the potential to detect a sugar molecule only present…
CSIRO unlocks new way to understand evolving strains of SARS-CoV-2
20 April 2020 Researchers from CSIRO, Australia’s national science agency, have unveiled a new approach to analysing the genetic codes – or the blueprint – of the SARS-CoV-2 virus that causes COVID-19. The findings will help researchers better…
Stepping up to shield our healthcare workers from infection
16 April 2020 RMIT engineers are 3D printing face shields for frontline healthcare workers in a rapid response to projected shortages during the pandemic. A team at the university’s Advanced Manufacturing Precinct (AMP) have so far made 950 prototype face…
Starpharma (ASX:SPL) compound shows activity against coronavirus
15 April 2020 Starpharma’s antiviral dendrimer, SPL7013, has been shown to have significant activity against SARS-CoV-2[1] (coronavirus), which causes COVID-19 SPL7013 is the active component in Starpharma’s range of marketed VivaGel® products[2] (VivaGel® BV and the VivaGel® condom), already sold in Australia, UK, Europe,…
PharmAust and Walter and Eliza Hall Institute to Evaluate Monepantel on COVID-19 Infection Model
17 April 2020 PharmAust has entered into a Materials Transfer Agreement with the Walter and Eliza Hall Institute of Medical Research in Melbourne, Victoria (“WEHI”). Under the Agreement, PharmAust will provide both monepantel and monepantel sulfone to WEHI,…
